By. Corina Dutcus, MD
Date. November 01, 2023
Corina Ductus, MD, a medical doctor and the Senior Vice President of Clinical Development at Eisai, recently addressed critical aspects of the Phase 3 Study 309/KEYNOTE-775 trial focusing on patients with advanced endometrial cancer. The trial specifically evaluated the efficacy of pembrolizumab in combination with lenvatinib for patients who had undergone prior platinum therapy.
During the interview, Dr. Ductus discussed the key findings from the trial. The research showcased significant improvements in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). These statistically and clinically significant enhancements in patient outcomes hold immense significance in the treatment landscape for advanced endometrial cancer. Dr. Ductus shed light on the importance of these findings within the context of providing potentially improved therapeutic options for this patient population.
One notable aspect of the trial involved patients with mismatch repair-proficient (pMMR) tumors. The results from this subset of patients revealed substantial implications for treatment options. Dr. Ductus emphasized how these outcomes with pembrolizumab and lenvatinib might potentially surpass the efficacy of standard chemotherapy, thereby opening up new avenues for tailored treatments for patients with pMMR tumors.
Moreover, Dr. Ductus touched upon the exploratory analysis conducted to assess outcomes in patients who completed 2 years of pembrolizumab and continued with lenvatinib. This long-term treatment approach was highlighted as an area warranting further investigation. The implications of this analysis might significantly influence the long-term treatment strategy for patients with advanced endometrial cancer.
Safety considerations were also discussed during the interview, emphasizing the need for further detailed investigation into the safety profile of this treatment regimen. Dr. Ductus highlighted the importance of understanding potential safety implications that might impact the broader treatment landscape. These considerations play a crucial role in shaping the perception and adoption of this treatment approach.
Dr. Corina Ductus, as a leading figure at Eisai, provided insightful commentary, offering a comprehensive understanding of the implications, possibilities, and considerations regarding the Phase 3 Study 309/KEYNOTE-775 trial for advanced endometrial cancer treatment. Her expertise and contribution to the field are invaluable in advancing the understanding and potential treatment options for this patient population.